TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 8-K

On September 16, 2026, Teva Pharmaceutical Industries Limited (the "Company") and its subsidiaries Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Teva Pharmaceutical Finance Netherlands IV B.V. (the "Issuers") completed a significant debt financing. The Issuers collectively issued €1,000,000,000 of 4.250% Senior Notes due 2033 and €500,000,000 of 4.625% Senior Notes due 2036, along with $1,000,000,000 of 5.500% Senior Notes due 2034, $1,000,000,000 of 5.750% Senior Notes due 2037, and $1,200,000,000 of 5.250% Senior Notes due 2032. The aggregate principal amount of notes issued is €1,500,000,000 and $2,200,000,000. The net proceeds from these notes are intended to fund the redemption of certain existing notes, cover related fees and expenses, and for general corporate purposes, including debt repayment. The notes are senior unsecured obligations, guaranteed on a senior unsecured basis by the Company. The financing involved multiple indentures and supplemental indentures, with The Bank of New York Mellon acting as trustee and paying agent.